---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-26-271071"
form_type: "8-K"
ticker: "LYEL"
cik: "0001806952"
company_name: "Lyell Immunopharma, Inc."
filed_at: "2026-06-15T20:05:50+00:00"
generated_at: "2026-06-15T20:16:19.219751+00:00"
event_type: "other"
sentiment: "neutral"
materiality_score: 0.1
calibrated_materiality_score: 0.1
confidence: "high"
source: SEC EDGAR
---

# Lyell Immunopharma shareholders elect three directors, ratify EY, approve say-on-pay at 2026 annual meeting

## Summary
- Quorum of 67.31% (15,706,826 shares) present; all three proposals passed.
- Elected Class II directors Richard Klausner, Otis Brawley, William Rieflin with >99.2% of votes cast in favor each.
- Ratified Ernst & Young as independent auditor for FY2026: 15,674,347 for, 30,758 against, 1,721 abstain.
- Advisory vote on named executive officer compensation passed: 11,860,218 for, 6,613 against, 410,709 abstain, 3,429,286 broker non-votes.

## SEC filing metadata
- accession: 0001193125-26-271071
- form_type: 8-K
- ticker: LYEL
- cik: 0001806952
- company_name: Lyell Immunopharma, Inc.
- filed_at: 2026-06-15T20:05:50+00:00
- event_type: other
- sentiment: neutral
- materiality_score: 0.1
- calibrated_materiality_score: 0.1
- confidence: high
- sec_items: 5.07
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1806952/000119312526271071/0001193125-26-271071-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1806952/000119312526271071/d102015d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-26-271071
- JSON: https://secwatch.observer/filing/0001193125-26-271071.json
- Plain text: https://secwatch.observer/filing/0001193125-26-271071.txt

## Key facts
- Shareholder Votes
  Lyell Immunopharma, Inc. shareholders approved Advisory vote on the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement at the 2026-06-10 meeting.
  - Proposal: say on pay
  - Outcome: passed
  - Meeting: 2026-06-10
  source text: To approve, on an advisory basis, the compensation of the Company’s named executive officers, as disclosed in the Proxy Statement. The voting results were as follows: Votes For Votes Against Abstentions Broker Non-Votes Total 11,860,218 6,613 410,709 3,429,286 15,706,826
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806952/000119312526271071/0001193125-26-271071-index.htm
- Shareholder Votes
  Lyell Immunopharma, Inc. shareholders approved Election of Class II directors to hold office until the Company's 2029 annual meeting of stockholders at the 2026-06-10 meeting.
  - Proposal: director election
  - Outcome: passed
  - Meeting: 2026-06-10
  source text: To elect the following Class II directors to hold office until the Company’s 2029 annual meeting of stockholders. The voting results were as follows: Name Votes For Votes Withheld Broker Non-Votes Total Richard Klausner, M.D. 12,177,913 99,627 3,429,286 15,706,826 Otis Brawley, M.D. 11,866,210 411,330 3,429,286 15,706,826 William Rieflin 12,192,547 84,993 3,429,286 15,706,826
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806952/000119312526271071/0001193125-26-271071-index.htm
- Shareholder Votes
  Lyell Immunopharma, Inc. shareholders approved Ratification of the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026 at the 2026-06-10 meeting.
  - Proposal: auditor ratification
  - Outcome: passed
  - Meeting: 2026-06-10
  source text: To ratify the appointment of Ernst & Young LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026. The voting results were as follows: Votes For Votes Against Abstentions Total 15,674,347 30,758 1,721 15,706,826
  evidence_url: https://www.sec.gov/Archives/edgar/data/1806952/000119312526271071/0001193125-26-271071-index.htm

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.